Merriman Curhan Downgrades Targanta (TARG) to Sell
More News related to TARG
- Medicines Company (MDCO) Commences Tender Offer for Targanta Therapeutics (TARG)
- Unusual 11 Mid-Day Movers 1/13: TARG, ZGEN, FIG, LXP Higher; BQI, RMBS, CPHD, LXK Lower
- Morning Movers 1/13: ZymoGenetics (ZGEN) Up On Bristol-Myers Deal; Lexmark (LXK) Down On Guidance
- The Medicines Co (MDCO) Acquires Targanta Therapeutics (TARG) For $2/Share
- Unusual 11 Mid-Day Movers 12/09: DRYS, CPE, XCO, EXM Higher; TARG, TRGT, ALOG, PBY Lower
More News related to Downgrades
- Standpoint Research Downgraded Deckers Outdoor (DECK) to Hold
- BGB Securities Downgrades Helmerich & Payne (HP) to Sell
- Sidoti & Co Downgrades Waste Services (WSII) to Neutral
- William Blair Downgrades Strayer (STRA), ITT (ESI) to Market Perform
- D.A. Davidson Downgrades Rocky Brands (RCKY) to Underperform
Merriman Curhan Ford downgrades Targanta Therapeutics (Nasdaq: TARG) from Buy to Sell.
Targanta Therapeutics Corporation, together with its subsidiaries, operates as a biopharmaceutical company that focuses on developing and commercializing antibacterial drugs to treat serious infections in hospital and other institutional settings.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
